TriangleNCT02689219 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Up to 2 years
What was measured
Duration of time from the start of treatment to time of death due to any causes. Patients who did not die were censored on their last known alive date. Kaplan-Meier methods will be used and the median and 95% confidence intervals will be calculated.
Analysis population: All patients who received at least one dose of study medication.
Groups in this outcome
CD30 Negative/Unknown
Brentuximab Vedotin 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle for CD30 Negative/Unknown cohort.
CD30 Positive
Brentuximab Vedotin 1.8 mg/ kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle for CD30 Positive cohort.
| Group | Source count |
|---|---|
| CD30 Negative/Unknown | 11 |
| CD30 Positive | 7 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| CD30 Negative/Unknown | 5.89 | Not reported | 1.64 | 8.19 | Not reported |
| CD30 Positive | 2.53 | Not reported | 1.12 | 12.89 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 1.64
- upper Limit
- 8.19
- value
- 5.89
- group Id
- OG001
- lower Limit
- 1.12
- upper Limit
- 12.89
- value
- 2.53
- denoms
- counts
- group Id
- OG000
- value
- 11
- group Id
- OG001
- value
- 7
- units
- Participants
- description
- Duration of time from the start of treatment to time of death due to any causes. Patients who did not die were censored on their last known alive date. Kaplan-Meier methods will be used and the median and 95% confidence intervals will be calculated.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Brentuximab Vedotin 1.8 mg/kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle for CD30 Negative/Unknown cohort.
- id
- OG000
- title
- CD30 Negative/Unknown
- description
- Brentuximab Vedotin 1.8 mg/ kg (1.2 mg/kg in patients with grade 2 peripheral neuropathy at enrollment) administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle for CD30 Positive cohort.
- id
- OG001
- title
- CD30 Positive
- param Type
- MEDIAN
- population Description
- All patients who received at least one dose of study medication.
- reporting Status
- POSTED
- time Frame
- Up to 2 years
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice